Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT05858268 for Cerebral Palsy is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
NeuralNET Cerebral Palsy Pilot Study 66
Clinical Trial NCT05858268 is an observational study for Cerebral Palsy that is active, not recruiting. It started on April 14, 2023 with plans to enroll 66 participants. Led by University of Cambridge, it is expected to complete by January 31, 2026. The latest data from ClinicalTrials.gov was last updated on March 30, 2025.
Brief Summary
The NeuralNET Cerebral Palsy Pilot Study is testing a genetic testing pathway in the NHS for children with cerebral palsy (CP). Other studies suggest that almost one in three peoples' CP is caused by a change in their genes, but more studies are needed to confirm this. A genetic test called whole genome sequencing (WGS) will be used for children who have CP to look for rare changes in genes that cause the condition, ...Show More
Official Title
The NeuralNET: Research to Impact Diagnosis, Mechanistic Understanding and Treatment of Children's Brain and Mental Health Disorders - A Pilot Study in Cerebral Palsy
Conditions
Cerebral PalsyOther Study IDs
- IRAS: 319781
NCT ID Number
Start Date (Actual)
2023-04-14
Last Update Posted
2025-03-30
Completion Date (Estimated)
2026-01-31
Enrollment (Estimated)
66
Study Type
Observational
Status
Active, not recruiting
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
N/A | Whole-genome sequencing Whole-genome sequencing |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Feasibility of rapid whole-genome sequencing of children with cerebral palsy | The investigators will measure feasibility of rapid whole-genome sequencing of children with cerebral palsy by successful delivery of WGS results to 66 children with a clinical diagnosis of CP within 12 weeks of blood sample receipt in the laboratory. | 16 months |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Uptake of WGS testing by families with a child with CP | The percentage of uptake of WGS testing by families with a child with CP will be measured by comparing the number of families invited to the study to the number who proceed with testing at baseline | Baseline |
Reasons for declining offer of WGS | The reasons for declining the offer of WGS provided by families voluntarily to the referring clinician will be measured in aggregate using a questionnaire at the close of the recruitment | 16 months |
Identification of specific genetic contributors to CP in the UK | Specific genetic contributors to CP in children in the UK will be measured using the collation of WGS results at the close of the recruitment | 16 months |
Parent/guardian intolerance for uncertainty | Intolerance of uncertainty of parent/guardian will be measured with the short version of the validated Intolerance for Uncertainty scale, which is a 12-item self-administered questionnaire where items are rated on a 5-point Likert scale where a higher score means higher intolerance of uncertainty. | baseline |
Parent/guardian attitude to genome sequencing | Four-item scale via self-administered questionnaire examining general attitudes (eg harmful vs. beneficial, unimportant vs. important, etc.) of parent/guardian to genome sequencing measured on a five-point Likert scale, where a higher score means more positive attitude. | baseline and 16 months |
Parent/guardian decisional conflict | Parent/guardian decisional conflict will be measured with validated sixteen-item self-administered questionnaire which assesses decisional certainty or conflict about a healthcare decision on a five-point Likert scale, where a higher score indicates higher uncertainty or conflict. | baseline |
Parent/guardian empowerment | Parent/guardian empowerment relating to genomic medicine will be measured with the Genomics Outcome Scale, a validated six-item self-administered questionnaire with a 5-point Likert scale, where a higher score indicates higher theoretical construct of empowerment. | baseline, 16 months |
Parent/guardian decisional regret | Parent/guardian decisional regret about WGS will be measured with a validated 5-item self-administered Decisional Regret Scale, which uses a 5-point Likert scale where higher scores indicate greater decisional regret. | 16 months |
Parent/guardian psychological impact of WGS | Parent/guardian psychological impact of WGS will be measured with adapted 10-item version of the validated Feelings About genomic Testing Results (FACToR) scale, which uses a 5-point Likert scale to measure agreement with specific feelings about the impact of result disclosure after genomic testing, where a higher score indicates greater agreement with those feelings. | 16 months |
Impact of WGS on family quality of life | Impact of WGS on the family's quality of life will be measured using the Family Impact Module of The PEDS-QL, which is a 36-item validated self-administered scale. It uses a 5-point Likert scale where higher scores indicated greater agreement with specific items. | 16 months |
Clinical utility of WGS testing in children with CP | The clinical utility of WGS testing in children with CP from the Paediatrician's perspective will measured using the validated Clinician-reported Genetic testing Utility InDEx (C-GUIDE), a self-administered questionnaire which includes 17 items related to results received for the primary indication for testing and 9 items related to secondary variant results received. Individual items scores range from -1 to 2. An item score \>0 indicates positive utility, item scores \<0 indicate presence of negative utility, and item scores of 0 indicate absence of utility. | 16 months |
Number of candidate variants which warrant further investigation of pathogenicity | Number of candidate variants which warrant further investigation of pathogenicity via collaborative studies will be measured by collating potentially pathogenic variants of uncertain significance at the completion of the study. | 16 months |
Generation of data to support the refinement of clinical criteria for WGS for CP | Data to support the refinement of clinical criteria for assessing CP patient suitability for WGS testing will be measured using the correlation of clinical features with identification of causative variants by WGS | 16 months |
Participation Assistant
Eligibility Criteria
Eligible Ages
Child
Eligible Sexes
All
Children with cerebral palsy (CP):
- Has a clinical diagnosis of CP in the medical record
- Any GMFCS score (GMFCS 1-5)
- Does not have a known genetic diagnosis that explains the CP phenotype
- Has a parent/legal guardian available who can consent and is willing to complete study questionnaires
- Invited to participate by a clinician at a participating recruitment site
Biological parents of children with CP will also be included in the study if they are:
- A biological parent of the child
- Aged 18 years or above
- Willing and able to give informed consent for participation in the study Participant type
Children with cerebral palsy (CP):
- Children that have a pre-existing genetic diagnosis from whole genome sequencing or whole-exome sequencing
- Children not matching the inclusion criteria
Biological parents of children with CP will be excluded from the study if they do not meet the biological parent inclusion criteria i.e. they ARE NOT:
- A biological parent of the child
- Aged 18 years or above
- Willing and able to give informed consent for participation in the study
University of Cambridge- 🏛️Rosetrees Trust
Study Responsible Party
Heather Pierce, Principal Investigator, Research Study Coordinator, University of Cambridge
No contact data.
1 Study Locations in 1 Countries
Cambridge University Hospitals NHS Trust, Cambridge, CB2 0QQ, United Kingdom